Pre-made Enoblituzumab biosimilar ( Whole mAb, anti-CD276 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-184
Anti-CD276 therapeutic antibody (Pre-made Enoblituzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Enoblituzumab is a monoclonal antibody designed for the treatment of cancer. Formerly known as MGA271, the drug is a humanized IgG1�� monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CD276 therapeutic antibody (Pre-made Enoblituzumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||MacroGenics;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|
|Conditions Active||Prostate cancer;Solid tumours;Head and neck cancer|
|Conditions Discontinued||Malignant melanoma;Non-small cell lung cancer;Squamous cell cancer;Urogenital cancer|